Indaptus Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Junyi Dai

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Aug 15

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Aug 08

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Sep 29

CEO

Junyi Dai (38 yo)

less than a year

Görev süresi

Mr. Junyi Dai is CEO & Chairman of Indaptus Therapeutics, Inc. from March 18, 2026. He had been an Independent Director of Mega Matrix Corp. from May 10, 2024 until December 30, 2025. He served as Managing...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Newman	Founder	4.7yrs	US$1.69m	4.51% $ 348.7k
Walt Linscott	Chief Operating Officer	3.1yrs	US$1.95m	2.43% $ 187.8k
Junyi Dai	CEO & Chairman	less than a year	Veri yok	Veri yok
Yu Ding	Chief Financial Officer	no data	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: INDP 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Newman	Founder	4.7yrs	US$1.69m	4.51% $ 348.7k
Junyi Dai	CEO & Chairman	less than a year	Veri yok	Veri yok
David Natan	Independent Director	less than a year	Veri yok	Veri yok
Jerome Jabbour	Independent Director	less than a year	Veri yok	Veri yok
Matthew McMurdo	Director	less than a year	Veri yok	1.11% $ 86.2k
Avraham Ben-Tzvi	Director	less than a year	Veri yok	1.12% $ 86.6k
David Lazar	Director	less than a year	Veri yok	Veri yok
Qinglai Lu	Independent Director	no data	Veri yok	Veri yok

0.2yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INDP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/19 14:59
Gün Sonu Hisse Fiyatı	2026/04/17 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Indaptus Therapeutics, Inc. 1 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jason McCarthy	Maxim Group

Indaptus Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Indaptus Therapeutics, Inc. Appoints David Natan as A Class II Director

Less than half of directors are independent

Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony Maddaluna

Indaptus Therapeutics, Inc., Annual General Meeting, Jun 10, 2025

Insufficient new directors

Recent updates

New major risk - Financial position

High number of new directors

Indaptus Therapeutics, Inc. Appoints David Natan as A Class II Director

Less than half of directors are independent

Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony Maddaluna

Forecast to breakeven in 2028

Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in funding

New major risk - Financial position

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.375 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. announced that it has received $3.4 million in funding

Indaptus Therapeutics, Inc. announced that it has received $2.3 million in funding

Indaptus Therapeutics Doses First Patient in Phase 1B/2 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor Tislelizumab

New minor risk - Share price stability

New major risk - Financial position

Indaptus Therapeutics, Inc., Annual General Meeting, Jun 10, 2025

New major risk - Market cap size

Indaptus Therapeutics, Inc. Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LP

Indaptus Therapeutics, Inc. Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirements

Indaptus Therapeutics, Inc. announced that it has received $2.246493 million in funding

New major risk - Shareholder dilution

Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding

New major risk - Market cap size

Insufficient new directors

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. Presents Clinical Data on Decoy20 at SITC 2024 Annual Meeting

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri